Steris Plc STE

Revenue Intelligence Report • 24 quarters of SEC filing data • Updated 2026-03-15

Steris Plc has a forecasted full-year revenue of $6.1B, a +6.6% year-over-year change, based on 24 quarters of SEC filing data. Key revenue drivers include R&D (elasticity 2.34x) and SG&A (elasticity 0.55x). The ARDL model achieves strong accuracy at 1.7% MAPE.

Investment Thesis

Our ARDL model tracks Steris Plc's revenue with exceptional precision (1.7% MAPE), indicating highly predictable cash flows. R&D investment shows a 2.34x multiplier — each 1% increase in R&D spend is associated with a 2.34% revenue increase, signaling strong innovation-to-revenue conversion. Sales & marketing spend shows a 0.55x elasticity, suggesting effective go-to-market execution.

Next FY Revenue
$6.10B
+6.6% YoY
R&D Elasticity
2.34x
SG&A Elasticity
0.55x
Model Accuracy
1.7% MAPE
Holdout validation: The model predicted $1.4B vs the actual $1.5B — an error of 7.5%.

Revenue Forecast

STE Revenue Forecast

Quarterly Detail

QuarterModel ForecastActual95% RangeYoY GrowthStatus
Q4 2025 $1.4B $1.5B $1.3B – $1.4B +4.2% ✗ Outside range
Q2 2026 $1.6B $1.5B – $1.7B +14.3%
Q3 2026 $1.4B $1.3B – $1.5B +1.7%
Q4 2026 $1.6B $1.5B – $1.7B +8.8%
Q1 2027 $1.5B $1.4B – $1.7B +2.1%

Seasonal Factors

Multiplicative seasonal adjustment: These factors capture Steris Plc's systematic quarterly revenue patterns relative to the trend model. A factor of 1.05 means that quarter typically runs 5% above the underlying trend; 0.95 means 5% below. Factors are computed as the median of (actual / fitted) across all available quarters.
Fiscal QuarterSeasonal Factorvs TrendInterpretationObs.
FQ1 (Sep–Nov) 0.9927 -0.7% In line with trend 7
FQ2 (Dec–Feb) 1.0113 +1.1% In line with trend 7
FQ3 (Mar–May) 1.0 +0.0% In line with trend 0
FQ4 (Jun–Aug) 0.9966 -0.3% In line with trend 6

How Spending Drives Revenue

STE Spending Timing
Reading this chart: Each line shows the cumulative elasticity — how a 1% increase in spending translates to revenue growth over subsequent quarters. The effect builds over 4-5 quarters as investments compound.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch

More in Healthcare

DHR REGN ALGN INCY BAX PFE ABBV IQV